• Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • NP and PA
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
  • Vitiligo
  • Wound Care

Article

New gel combats itching, pain from certain wounds

Author(s):

Petaluma, Calif. - Medical technology company Oculus Innovative Sciences is bringing Microcyn Dermatology HydroGel to the U.S. market, Business Wire reports.

Petaluma, Calif. - Medical technology company Oculus Innovative Sciences is bringing Microcyn Dermatology HydroGel to the U.S. market, Business Wire reports.

Oculus, of Petaluma, Calif., recently announced that it had received Food and Drug Administration (FDA) clearance for the product. The gel, to be used by patients under the supervision of a healthcare professional, is intended for management of wounds including itch and pain relief associated with dermal irritation, sores, injuries and ulcers of dermal tissue.

According to Business Wire, the company is preparing for six additional FDA regulatory clearances for multiple indications including oral, allergy and expanded dermatology claims.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

© 2025 MJH Life Sciences

All rights reserved.